Results 51 to 60 of about 4,011 (178)

Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice

Pulmonary Circulation, 2019
Pulmonary fibrosis is a progressive disease characterized by disruption of lung architecture and deregulation of the pulmonary function. Prostacyclin, a metabolite of arachidonic acid, is a potential disease mediator since it exerts anti-inflammatory and
Ioanna Nikitopoulou, Nikolaos Manitsopoulos, Anastasia Kotanidou, Xia Tian, Aleksandar Petrovic, Christina Magkou, Ioanna Ninou, Vassilis Aidinis, Ralph T. Schermuly, Djuro Kosanovic, Stylianos E. Orfanos   +10 more
doaj   +1 more source

Contemporary Concise Review 2025: Interstitial Lung Disease

Respirology, EarlyView.
ABSTRACT Multidisciplinary discussion remains the cornerstone of ILD diagnosis and management, with recent advances further strengthening the integration of clinical, radiological, pathological, and molecular information. Updated ILD nomenclature and classification better align disease terminology with underlying morphology and pathobiology.
Tonia Magrì, Luca Richeldi
wiley   +1 more source

A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9423-9432, October 2026.
ABSTRACT Aims To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 [500 U/mL]; AT278‐U500) compared with standard concentration insulin aspart (InsAsp [100 U/mL]; InsAsp‐U100) and U500 human regular insulin (HumIns [500 IU/mL]; HumIns‐U500). Materials and Methods This single‐centre, randomised,
Eva Svehlikova, Christina Gatschelhofer, Bettina Lackner, Maria Ratzer, Gabriele Fluhr, Anja Stoisser, Gregor Kolaric, David Gerring, Sarah Howell, Jan Jezek, Fiona Lawrence, Thomas R. Pieber   +11 more
wiley   +1 more source

The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension

Case Reports in Pulmonology, 2015
In patients who require urgent initiation of pulmonary arterial hypertension medications due to disease progression, it is customary to start intravenous prostacyclin therapy, typically during a hospital admission.
James Benjamin Gleason, Justin Dolan, Pirouz Piran, Franck Farzad Rahaghi   +3 more
doaj   +1 more source

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study

Drugs - Real World Outcomes, 2020
Background Given the improved convenience of oral prostacyclins, there is a shift toward their use in treating pulmonary arterial hypertension (PAH).
Bonnie B. Dean, Vishal Saundankar, Dana Stafkey-Mailey, Rebekah H. Anguiano, Andrew C. Nelsen, Kathryn Gordon, Peter Classi   +6 more
doaj   +1 more source

Beraprost Attenuates Starvation‐Induced Apoptosis and Protects Feline Endothelial Cells

Veterinary Medicine and Science, Volume 12, Issue 5, September 2026.
This study established a feline endothelial cell starvation model to test the anti‐apoptotic effects of beraprost and its stereoisomers. Beraprost and beraprost‐314d reduced starvation‐induced apoptosis by inhibiting caspase‐3/7 activity and modulating Bax expression, while beraprost‐315d was less potent.
Takumi Matsuura, Cris Niño Bon B. Marasigan, Tomohiro Yonezawa   +2 more
wiley   +1 more source

Non‐HLA Antibody‐Associated Hyperacute Allograft Rejection Following Lung Transplantation

Pediatric Transplantation, Volume 30, Issue 9, September 2026.
ABSTRACT Background Pediatric‐onset pulmonary hypertension (PH) is a rare, progressive pulmonary vascular disease associated with high mortality. In cases unresponsive to pharmacological therapy with a severe cardiorespiratory phenotype, lung transplantation (LT) remains the final treatment option. Although LT for pediatric PH is considered a procedure
Justyna A. Karolak, Ernestina Melicoff, Nidhy P. Varghese, Przemyslaw Szafranski, Esra Yıldız Bölükbaşı, Erin E. McHugh, Sarah Nicholas, Peter Jindra, John Hicks, Eric D. Austin, Paweł Stankiewicz, George B. Mallory   +11 more
wiley   +1 more source

Treprostinil for pulmonary hypertension

, 2004
Treprostinil (Remodulin, United Therapeutics) is a stable, long-acting prostacyclin analog, which has been shown to improve clinical state, functional class, exercise capacity and quality of life in patients with pulmonary arterial hypertension, an ...
Vachiery, Jean-Luc, Naeije, Robert
core   +1 more source

Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies

Pulmonary Circulation, 2020
The 2015 European Society of Cardiology/European Respiratory Society treatment guidelines recommend frequent risk assessment in pulmonary arterial hypertension utilizing risk variables.
Adriano R. Tonelli, Sandeep Sahay, Kathryn W. Gordon, Lisa D. Edwards, Andrew G. Allmon, Meredith Broderick, Andrew C. Nelsen   +6 more
doaj   +1 more source

Right Ventricular Function Improves With Pulmonary Vasodilator Treatment in Pediatric Patients With Pulmonary Hypertension and Multivessel Pulmonary Vein Stenosis in a Single Center Cohort

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary hypertension (PH) and right ventricular (RV) dysfunction increase mortality in multivessel pediatric pulmonary vein stenosis (PVS). Pulmonary vasodilator use is limited in PVS due to the perceived risk of pulmonary edema. We aimed to describe our experience with pulmonary vasodilators in PVS and to assess changes in RV function and ...
Catherine M. Avitabile, Kimberly Butler, Antara Mondal, David B. Frank, Yan Wang, Devon Ash, Laura Mercer‐Rosa, Michael L. O'Byrne, Ryan Callahan   +8 more
wiley   +1 more source